company background image
CLSD logo

Clearside Biomedical NasdaqGM:CLSD Stock Report

Last Price

US$1.41

Market Cap

US$105.4m

7D

22.6%

1Y

31.8%

Updated

23 Apr, 2024

Data

Company Financials +

Clearside Biomedical, Inc.

NasdaqGM:CLSD Stock Report

Market Cap: US$105.4m

CLSD Stock Overview

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.

CLSD fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Clearside Biomedical, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Clearside Biomedical
Historical stock prices
Current Share PriceUS$1.41
52 Week HighUS$2.12
52 Week LowUS$0.65
Beta2.33
1 Month Change-17.54%
3 Month Change14.63%
1 Year Change31.78%
3 Year Change-54.81%
5 Year Change13.71%
Change since IPO-80.55%

Recent News & Updates

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12
Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11
Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30
Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17
We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16
If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Clearside Biomedical's early-stage wet AMD study gets underway

Jan 12

Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares

Jan 12
Trade Alert: Bradford Whitmore At Clearside Biomedical, Inc. (NASDAQ:CLSD), Has Just Spent US$1m Buying 11% More Shares

Clearside Bio drops 11% on launch of $12M direct offering

Jan 06

Clearside Biomedical: SCS Microinjector Platform With Significant Upside

Jan 05

Do Institutions Own Clearside Biomedical, Inc. (NASDAQ:CLSD) Shares?

Dec 30
Do Institutions Own Clearside Biomedical, Inc. (NASDAQ:CLSD) Shares?

Shareholder Returns

CLSDUS PharmaceuticalsUS Market
7D22.6%-1.5%-3.2%
1Y31.8%9.7%19.3%

Return vs Industry: CLSD exceeded the US Pharmaceuticals industry which returned 9.7% over the past year.

Return vs Market: CLSD exceeded the US Market which returned 19.3% over the past year.

Price Volatility

Is CLSD's price volatile compared to industry and market?
CLSD volatility
CLSD Average Weekly Movement13.3%
Pharmaceuticals Industry Average Movement9.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: CLSD's share price has been volatile over the past 3 months.

Volatility Over Time: CLSD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201130George Lasezkayclearsidebio.com

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.

Clearside Biomedical, Inc. Fundamentals Summary

How do Clearside Biomedical's earnings and revenue compare to its market cap?
CLSD fundamental statistics
Market capUS$105.36m
Earnings (TTM)-US$32.48m
Revenue (TTM)US$8.23m

12.8x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLSD income statement (TTM)
RevenueUS$8.23m
Cost of RevenueUS$355.00k
Gross ProfitUS$7.87m
Other ExpensesUS$40.36m
Earnings-US$32.48m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.43
Gross Margin95.68%
Net Profit Margin-394.91%
Debt/Equity Ratio-263.9%

How did CLSD perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.